A method, comprising: using at least one computer hardware processor to perform: obtaining nucleic acid data comprising: sequence data indicating a nucleotide sequence for at least 5 kilobases (kb) of DNA and/or RNA from a previously obtained biological sample of a subject having, suspected of having, or at risk of having a disease, wherein the sequence data comprises one or more of whole exome sequencing data, whole genome sequencing data, and non-targeted mRNA enriched cDNA sequencing data; and asserted information indicating an asserted source and/or an asserted integrity of the sequence data; and validating the nucleic acid data by: processing the sequence data to obtain determined information indicating a determined source and/or a determined integrity of the sequence data; determining whether the determined information matches the asserted information; and processing the sequence data to determine whether the sequence data is indicative of one or more disease features when it is determined that the asserted information matches the determined information; wherein the asserted information for the sequence data comprises MHC allele information for the subject, and wherein the determined information comprises one or more MHC allele sequences from the sequence data. obtaining nucleic acid data comprising: sequence data indicating a nucleotide sequence for at least 5 kilobases (kb) of DNA and/or RNA from a previously obtained biological sample of a subject having, suspected of having, or at risk of having a disease, wherein the sequence data comprises one or more of whole exome sequencing data, whole genome sequencing data, and non-targeted mRNA enriched cDNA sequencing data; and asserted information indicating an asserted source and/or an asserted integrity of the sequence data; and sequence data indicating a nucleotide sequence for at least 5 kilobases (kb) of DNA and/or RNA from a previously obtained biological sample of a subject having, suspected of having, or at risk of having a disease, wherein the sequence data comprises one or more of whole exome sequencing data, whole genome sequencing data, and non-targeted mRNA enriched cDNA sequencing data; and asserted information indicating an asserted source and/or an asserted integrity of the sequence data; and validating the nucleic acid data by: processing the sequence data to obtain determined information indicating a determined source and/or a determined integrity of the sequence data; determining whether the determined information matches the asserted information; and processing the sequence data to determine whether the sequence data is indicative of one or more disease features when it is determined that the asserted information matches the determined information; processing the sequence data to obtain determined information indicating a determined source and/or a determined integrity of the sequence data; determining whether the determined information matches the asserted information; and processing the sequence data to determine whether the sequence data is indicative of one or more disease features when it is determined that the asserted information matches the determined information;